Long-term engrafting multilineage hematopoietic cells differentiated from human induced pluripotent stem cells

Elizabeth S Ng,Gulcan Sarila,Jacky Y Li,Hasindu S Edirisinghe,Ritika Saxena,Shicheng Sun,Freya F Bruveris,Tanya Labonne,Nerida Sleebs,Alexander Maytum,Raymond Y Yow,Chantelle Inguanti,Ali Motazedian,Vincenzo Calvanese,Sandra Capellera-Garcia,Feiyang Ma,Hieu T Nim,Mirana Ramialison,Constanze Bonifer,Hanna K A Mikkola,Edouard G Stanley,Andrew G Elefanty
DOI: https://doi.org/10.1038/s41587-024-02360-7
2024-09-02
Abstract:Hematopoietic stem cells (HSCs) derived from human induced pluripotent stem cells (iPS cells) have important biomedical applications. We identified differentiation conditions that generate HSCs defined by robust long-term multilineage engraftment in immune-deficient NOD,B6.Prkdcscid Il2rgtm1Wjl/SzJ KitW41/W41 mice. We guided differentiating iPS cells, as embryoid bodies in a defined culture medium supplemented with retinyl acetate, through HOXA-patterned mesoderm to hemogenic endothelium specified by bone morphogenetic protein 4 and vascular endothelial growth factor (VEGF). Removal of VEGF facilitated an efficient endothelial-to-hematopoietic transition, evidenced by release into the culture medium of CD34+ blood cells, which were cryopreserved. Intravenous transplantation of two million thawed CD34+ cells differentiated from four independent iPS cell lines produced multilineage bone marrow engraftment in 25-50% of immune-deficient recipient mice. These functionally defined, multipotent CD34+ hematopoietic cells, designated iPS cell-derived HSCs (iHSCs), produced levels of engraftment similar to those achieved following umbilical cord blood transplantation. Our study provides a step toward the goal of generating HSCs for clinical translation.
What problem does this paper attempt to address?